Prevention And Treatment of HypertensionWith Algorithm-based therapy (PATHWAY) number 2: Protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension

BMJ Open

Volumn 5, Issue 8, 2015, Pages

  Williams, Bryan ^a   MacDonald, Thomas M ^b   Caulfield, Mark ^c   Kennedy Cruickshank, J ^d   McInnes, Gordon ^e   Sever, Peter ^f   Webb, David J ^g   Salsbury, Jackie ^h   Morant, Steve ^h   Ford, Ian ^e   Brown, Morris J ^h  

^a Queen Mary University of London and Barts NIHR BRC NHS Trust National Institute for Health and Care Research   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; PLACEBO; RENIN; SPIRONOLACTONE; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG TOLERABILITY; FEMALE; HEMODYNAMICS; HOME MONITORING; HUMAN; HYPERTENSION; MALE; MAXIMUM TOLERATED DOSE; MEDICAL AUDIT; MULTICENTER STUDY; NON INVASIVE PROCEDURE; PHARMACOGENETICS; PLASMA RENIN ACTIVITY; QUALITY CONTROL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; RISK ASSESSMENT; SAMPLE SIZE; SODIUM RETENTION; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; ALGORITHM; COMBINATION DRUG THERAPY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL PROTOCOLS; CROSS-OVER STUDIES; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SPIRONOLACTONE; YOUNG ADULT;

EID: 84941552054     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008951     Document Type: Article

References (25)

1. Myat A, Redwood SR, Qureshi AC, et al. Resistant hypertension. BMJ 2012;345:e7473.
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
3. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19.
4. Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ 2011;343:d4891.
5. NICE hypertension guideline CG127. https://www.nice.org.uk/guidance/cg127 (accessed 26 May 2015).
6. Düsing R. Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag 2010;6:321-5.
7. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009;54:475-81.
8. Brown MJ. Renin: friend or Foe? Heart 2007;93:1026-33.
9. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45.
10. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16(11 Pt 1):925-30.
11. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: A surveillance study. J Hypertens 2007;25:891-4.
12. Hood SJ, Taylor KP, Ashby MJ, et al. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007;116:268-75.
13. British Hypertension Society how to measure blood pressure. http://www.bhsoc.org/latest-guidelines/how-to-measure-blood-pressure/(accessed 26 May 2015).
14. Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014;100:855-61.
15. Pathway 1 BMJ Open 2015-to be inserted by BMJ Open.
16. Pathway 3 BMJ Open 2015-to be inserted by BMJ Open.
17. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57:898-902.
18. Myat A, Redwood SR, Qureshi AC, et al. Renal sympathetic denervation therapy for resistant hypertension: A contemporary synopsis and future implications. Circ Cardiovasc Interv 2013;6:184-97.
19. Bhatt DL, Kandzari DE, O'Neill WW, et al. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393-401.
20. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20.
21. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014;32:3-15.
22. Kjeldsen S, Feldman RD, Lisheng L, et al. Updated national and international hypertension guidelines: A review of current recommendations. Drugs 2014;74:2033-51.
23. Chapman N, Chang CL, Dahlöf B, et al. ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008;118: 42-8.
24. Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hypertension. JAMA 1979;241:151-6.
25. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002;39:982-8.